S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
Log in
NASDAQ:FDMT

4D Molecular Therapeutics Stock Forecast, Price & News

$46.71
-0.29 (-0.62 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$46.37
Now: $46.71
$48.23
50-Day Range N/A
52-Week Range
$35.01
Now: $46.71
$51.00
Volume184,166 shs
Average Volume149,705 shs
Market Capitalization$1.18 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for 4D Molecular Therapeutics Inc.

MarketRank

Overall MarketRank

0.93 out of 5 stars

Medical Sector

1025th out of 1,926 stocks

Analyst Opinion: 1.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FDMT
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.18 billion
Next Earnings DateN/A
OptionableNot Optionable
$46.71
-0.29 (-0.62 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FDMT News and Ratings via Email

Sign-up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











4D Molecular Therapeutics (NASDAQ:FDMT) Frequently Asked Questions

Is 4D Molecular Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" 4D Molecular Therapeutics stock.
View analyst ratings for 4D Molecular Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than 4D Molecular Therapeutics?

Wall Street analysts have given 4D Molecular Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 4D Molecular Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as 4D Molecular Therapeutics' CEO?

1,448 employees have rated 4D Molecular Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among 4D Molecular Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What price target have analysts set for FDMT?

3 Wall Street analysts have issued 12 month target prices for 4D Molecular Therapeutics' stock. Their forecasts range from $44.00 to $47.00. On average, they expect 4D Molecular Therapeutics' share price to reach $45.50 in the next twelve months. This suggests that the stock has a possible downside of 2.6%.
View analysts' price targets for 4D Molecular Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of 4D Molecular Therapeutics' key competitors?

When did 4D Molecular Therapeutics IPO?

(FDMT) raised $101 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

What is 4D Molecular Therapeutics' stock symbol?

4D Molecular Therapeutics trades on the NASDAQ under the ticker symbol "FDMT."

When did 4D Molecular Therapeutics' quiet period expire?

4D Molecular Therapeutics' quiet period expired on Wednesday, January 20th. 4D Molecular Therapeutics had issued 8,400,000 shares in its IPO on December 11th. The total size of the offering was $193,200,000 based on an initial share price of $23.00. During 4D Molecular Therapeutics' quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is 4D Molecular Therapeutics' stock price today?

One share of FDMT stock can currently be purchased for approximately $46.71.

How big of a company is 4D Molecular Therapeutics?

4D Molecular Therapeutics has a market capitalization of $1.18 billion.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.